EU expands Hympavzi approval to hemophilia patients with inhibitors

Pfizer said on May 13, 2026, that the European Commission expanded Hympavzi’s approval to include adults and adolescents age 12 and older, weighing at least 35 kg, with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors. The decision broadens the label beyond Hympavzi’s earlier EU approval in patients without inhibitors and gives this harder-to-treat group access to a once-weekly, subcutaneous anti-TFPI therapy. Pfizer said the expansion was supported by Phase 3 BASIS data showing a statistically significant and clinically relevant reduction in treated annualized bleeding rate versus on-demand therapy. (pfizer.com)

Why it matters: For clinicians, the approval adds a non-factor prophylaxis option for inhibitor patients, a population with fewer treatment choices and more complex care pathways. Hympavzi also stands out because it’s designed for once-weekly administration and, according to Pfizer, does not require routine treatment-related lab monitoring. That said, the drug’s mechanism carries an acknowledged thrombosis risk, and hemophilia groups including the World Federation of Hemophilia and the National Bleeding Disorders Foundation have already highlighted a fatal thrombotic stroke reported in late 2025 in a person receiving marstacimab after minor surgery, underscoring the need for careful patient selection, perioperative planning, and safety monitoring. (pfizer.com)

What to watch: Watch for EU launch timing, uptake in inhibitor patients, and whether additional regulatory decisions follow for younger pediatric populations and other label expansions. (pfizer.com)